近日，东营市知识产权保护中心组织召开"助企攀登"审查员齐鲁行活动线上对接会，国家知识产权局专利局专利审查协作天津中心实践 团成员及相关负责同志，胜利油田胜机石油装备有限公司、东营坤宝新材料有限公司知识产权工作负责人，保护中心相关同志参加会 议。 会上，天津审协实践团负责人详细介绍了本次齐鲁行活动的目标、任务及服务方案，并表示将充分发挥专业审查员的优势，通过专利检 索分析、知识产权布局指导、侵权风险预警等服务，帮助企业提升知识产权创造、运用和保护能力。参会企业代表分别介绍了企业发展 概况，并结合自身发展实际，提出了高价值专利培育、专利深度挖掘等方面的需求。双方围绕企业现阶段重点研发产品和未来发展规 划，就专利微导航项目主题进行了深入探讨。 "助企攀登"专利审查员齐鲁行活动是以国家级审查资源为依托，通过"面对面"交流、"点对点"服务，帮助企业完善核心专利布局，推进 核心技术研发质效，自活动开展以来，东营市已有7家企业入选。下一步，东营市知识产权保护中心将继续发挥桥梁纽带作用，推动实践 团与企业精准对接，争取优质知识产权服务资源向更多企业延伸，确保服务落地见效。(大众新闻记者杜美萱通讯员刘新东韩伟) ...

8月8日至12日，2025世界机器人大会在北京亦庄举行，同期举行2025世界机器人博览会。大会以"让机 器人更智慧，让具身体更智能"为主题，展示内容重点聚焦前沿技术创新、机器人应用场景拓展等。记 者深入探访博览会发现，从工业生产线到手术室，从仓储物流到家庭服务，中国机器人产业正以专利布 局为基石，以场景创新为引擎，加速书写"人机共生"的未来图景。 人形机器人走入寻常百姓家 在沈阳新松机器人自动化股份有限公司（下称新松公司）的展位上，具身智能展区的人形机器人成为全 场焦点。新松智能类人双臂平台凭借多模态大模型交互能力，自主完成饮水机接水全流程作业，其脑、 眼、双手的精确协作让人惊叹。新松公司首席技术官张雷介绍，该平台采用正向开发设计，机器人本 体、底层控制系统及关节、控制器等核心零部件均为自主研发。"核心技术自主可控是我们的底气，而 专利布局则让这份底气有了法律保障。"张雷表示。 在北京长木谷医疗科技股份有限公司（下称长木谷）的展台，新一代骨科手术机器人 ROPA正通过三维 重建技术为观众演示髋关节置换手术规划。作为北京市首台（套）重大技术装备与国家工业和信息化 部、国家卫生健康委员会联合认定的高端医疗装备推广 ...

Core Viewpoint - Transsion Holdings is facing a patent dispute with Huawei, marking the second lawsuit from Huawei, reflecting the intensifying competition in the smartphone market where patent strategies are crucial [1][2]. Group 1: Patent Disputes - Huawei has filed a lawsuit against Transsion Holdings for allegedly infringing on its image display-related patent, specifically patent EP2725797, which was first applied for in June 2011 [1][2]. - Transsion Holdings has been involved in multiple patent disputes, including a previous lawsuit from Huawei in October 2019 regarding wallpaper infringement, where Huawei sought compensation of 20 million yuan [2]. - The ongoing patent disputes highlight the competitive landscape of the smartphone industry, where patent portfolios are becoming a key element of corporate strategy [2]. Group 2: Market Performance - Transsion Holdings reported a revenue of 68.715 billion yuan for the year 2024, a year-on-year increase of 10.31%, but the growth rate has significantly slowed compared to 33.69% in 2023 [4]. - In Q1 2025, the company experienced a revenue decline of 25.45% year-on-year, with net profit dropping by 69.87%, marking three consecutive quarters of declining performance [4]. - The African market, which is Transsion's primary base, saw revenue growth of only 2.97% in 2024, a decrease of 3.77 percentage points compared to the previous year, indicating weakening growth momentum [4]. Group 3: High-End Market Strategy - Transsion Holdings is accelerating its efforts to enter the mid-to-high-end market, as evidenced by the launch of the TECNO PHANTOM Ultimate G Fold, a concept foldable phone [5][6]. - Industry experts caution that the challenges for foldable phones extend beyond hardware, including insufficient market demand and high R&D costs, which may hinder profitability [6]. - The company's strategy to enhance its brand image through concept products is still unproven, and the effectiveness of this approach remains to be seen [6]. Group 4: Non-Mobile Business Development - Transsion Holdings has been diversifying into mobile internet services, digital accessories, and home appliances, with brands like oraimo and Syinix [7]. - However, the contribution of these non-mobile businesses to overall revenue is minimal, accounting for only 4.259 billion yuan, or less than 10% of total revenue in 2024 [7].

Group 1 - The core patent of Dongyangguang Pharmaceutical's invention "Bridge cyclic compound as a hepatitis C inhibitor and its preparation method" has won the second Hubei Patent Gold Award, highlighting the company's innovation and core competitiveness in new drug development [1][5][12] - The hepatitis C virus (HCV) infection rate in China is approximately 10 million, with new reported cases around 200,000 per year, indicating a significant public health challenge due to low diagnosis and treatment rates [6][7] - Dongyangguang Pharmaceutical established its research goal in 2010 to develop hepatitis C drugs tailored for the Chinese market, aiming to provide effective treatment options for the large patient population [6][7] Group 2 - The drug, Phosphoric acid imetavine, was developed over ten years and became the first domestically developed hepatitis C NS5A inhibitor in China, receiving approval in 2020 [7][8] - Phosphoric acid imetavine has a high overall cure rate of 99.8% when used in combination with Sofosbuvir, and it was included in the national medical insurance directory in December 2021, significantly reducing the cost for patients [7][8] - The patent strategy for Phosphoric acid imetavine includes a comprehensive layout that began in 2013 and has expanded to cover various aspects of the drug, enhancing its market competitiveness and protecting its innovations [10][11] Group 3 - Since its establishment in 2001, Dongyangguang Pharmaceutical has focused on R&D, applying for over 2,400 invention patents and holding more than 1,400 authorized patents, making it a leader in patent filings among domestic pharmaceutical companies [12] - The company has built a complete innovation chain from basic research to clinical transformation, with 150 approved drugs globally and over 100 in development, including nearly 50 first-class innovative drugs [12] - Dongyangguang Pharmaceutical aims to continue driving development through innovation, enhancing its core competitiveness, and contributing to the high-quality development of the pharmaceutical industry [12]

Core Points - Jiangsu province achieved significant recognition in the 25th China Patent Awards, with a total of 89 patents awarded, including 3 gold, 5 silver, and 73 excellence awards, positioning it among the top provinces in the country [1] - The awarded patents span cutting-edge technology fields such as bio-based materials, cell therapy drugs, and robotic sensors, addressing industry pain points and enhancing technology transfer through systematic patent strategies [1][2] Group 1: High-Value Patents - The gold award-winning patent from Nanjing University of Technology focuses on a method for producing bio-based polyols from plant oils, which can replace petrochemical products in various applications, including foams and coatings [2] - The silver award-winning patent for universal CAR-T cell therapy developed by Xuzhou Medical University addresses significant challenges in cancer treatment, potentially reducing treatment costs by 90% and showing promising preclinical results [3] - The patent for a method and device for repairing high-speed train gears, awarded excellence, enhances processing precision to the micron level, showcasing advancements in gear transmission technology [4] Group 2: Patent Strategy and Protection - The patent for a high-sensitivity six-dimensional force sensor from Southeast University, which has applications in aerospace and robotics, emphasizes the importance of creating a patent "protection circle" to safeguard innovations [5] - The team at Xuzhou Medical University has shifted from a single protection approach to a comprehensive strategy covering core technologies and production processes, applying over 50 domestic and international patents in recent years [6] Group 3: Industrial Value of Patents - Jiangsu's patent landscape has transitioned from quantity to quality, with a focus on accelerating the conversion of technological achievements into productive forces [7] - Jiangsu Hengrui Medicine has applied for a total of 2,609 invention patents in Greater China, with a focus on innovative drugs, highlighting the strategic importance of patents as valuable assets for pharmaceutical companies [7] - The silver award-winning patent for low-ash carbon fiber production method addresses high-end manufacturing needs, significantly reducing impurities that affect product quality [8] Group 4: Application and Market Expansion - The six-dimensional force sensor technology is being adapted for medical applications, including micro sensors for surgical robots, indicating a broadening of its market potential [9] - The development of low-ash carbon fiber technology meets the urgent demands of high-end manufacturing sectors, showcasing the practical application of awarded patents [8]